Abstract

BackgroundBoth Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV) are members of the human gamma herpesvirus family: each is associated with various human cancers. The majority of AIDS-associated primary effusion lymphoma (PEL) are co-infected with both KSHV and EBV. Dually-infected PELs selectively switch from latency to lytic replication of either KSHV or EBV in response to chemical stimuli. KSHV replication and transcription activator (K-RTA) is necessary and sufficient for the switch from KSHV latency to lytic replication, while EBV BZLF1 gene product (EBV-Z) is a critical initiator for induction of EBV lytic replication.Methodology/Principal FindingsWe show K-RTA and EBV-Z are co-localized and physically interact with each other in dually-infected PELs. K-RTA inhibits the EBV lytic replication by nullifying EBV-Z-mediated EBV lytic gene activation. EBV-Z inhibits KSHV lytic gene expression by blocking K-RTA-mediated transactivations. The physical interaction between K-RTA and EBV-Z are required for the mutual inhibition of the two molecules. The leucine heptapeptide repeat (LR) region in K-RTA and leucine zipper region in EBV-Z are involved in the physical interactions of the two molecules. Finally, initiation of KSHV lytic gene expression is correlated with the reduction of EBV lytic gene expression in the same PEL cells.Conclusions/SignificanceIn this report, how the two viruses interact with each other in dually infected PELs is addressed. Our data may provide a possible mechanism for maintaining viral latency and for selective lytic replication in dually infected PELs, i.e., through mutual inhibition of two critical lytic replication initiators. Our data about putative interactions between EBV and KSHV would be applicable to the majority of AIDS-associated PELs and may be relevant to the pathogenesis of PELs.

Highlights

  • Epstein-Barr virus (EBV) and Kaposi sarcoma (KS)-associated herpesvirus (KSHV), called human herpesvirus 8 (HHV-8), are the two gamma herpesviruses currently identified in humans

  • KSHV replication and transcription activator (K-RTA) was transfected into Akata cells, an EBV+/Kaposi’s sarcoma-associated herpesvirus (KSHV)- Buikitts’ lymphoma (BL) line, and the lytic replication of EBV was induced after the treatment with anti-human-immunoglobulin G (IgG) (See Materials and Methods for details)

  • We have provided evidence that the critical lytic replication initiators of KSHV and EBV interact at molecular levels

Read more

Summary

Introduction

Epstein-Barr virus (EBV) and Kaposi sarcoma (KS)-associated herpesvirus (KSHV), called human herpesvirus 8 (HHV-8), are the two gamma herpesviruses currently identified in humans. KSHV is believed to be the etiological agent of KS [6,7,8], and is implicated in the pathogenesis of AIDS-associated primary effusion lymphoma (PEL), called body cavity-based lymphoma (BCBL), and multicentric Castleman’s disease [6,9,10] Like other herpesviruses, both EBV and KSHV have latency and lytic replication in their life cycles. K-RTA interacts with other factors to modulate its transcription potential, and some interactions are ctritical for K-RTA-mediated switch from latency to lytic replication [19,20,21,22,23,24] Both Kaposi’s sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV) are members of the human gamma herpesvirus family: each is associated with various human cancers. KSHV replication and transcription activator (K-RTA) is necessary and sufficient for the switch from KSHV latency to lytic replication, while EBV BZLF1 gene product (EBV-Z) is a critical initiator for induction of EBV lytic replication

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.